Jul 2026
Abstract IA06: Title of the talk: KRAS - Degrading the Undruggable
This work developed panKRAS degraders using a structure-guided strategy combining reversible KRAS binders with VHL-recruiting PROTACs and enables potent pan-allelic degradation, including ON-biased mutants, establishing KRAS degradation as a viable therapeutic modality and positioning ACBI4 as a pioneering panKRAS ON/OFF chemical probe.
A. Mantoulidis
· Clinical Cancer Research · 0 citations